Effects of Intravenous Delivery of Longeveron Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody Responses in Subjects With Aging Frailty

Trial Profile

Effects of Intravenous Delivery of Longeveron Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody Responses in Subjects With Aging Frailty

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Mesenchymal stem cell therapy-Longeveron (Primary)
  • Indications Asthenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HERA
  • Sponsors Longeveron
  • Most Recent Events

    • 15 May 2017 Results from this trial have been published in Journals of Gerontology, according to a Longeveron Pharmaceuticals media release.
    • 08 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top